Next Article in Journal
Improved Histone Deacetylase Inhibitors as Therapeutics for the Neurodegenerative Disease Friedreich’s Ataxia: A New Synthetic Route
Previous Article in Journal
Essential Oils from Different Plant Parts of Eucalyptus cinerea F. Muell. ex Benth. (Myrtaceae) as a Source of 1,8-Cineole and Their Bioactivities
Previous Article in Special Issue
Vasoinhibins Prevent Bradykinin-Stimulated Endothelial Cell Proliferation by Inactivating eNOS via Reduction of both Intracellular Ca2+ Levels and eNOS Phosphorylation at Ser1179
Article Menu

Export Article

Open AccessReview
Pharmaceuticals 2011, 4(12), 1551-1577; doi:10.3390/ph4121551

Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix

1
Cell Signaling, Retinal and Tumor Angiogenesis Laboratory, Department of Genetics, Boys Town National Research Hospital, Omaha, NE 68131, USA
2
Department of Biochemistry and Molecular Biology, University of Nebraska Medical Center, Omaha, NE 68198, USA
*
Author to whom correspondence should be addressed.
Received: 14 October 2011 / Revised: 24 November 2011 / Accepted: 25 November 2011 / Published: 2 December 2011
(This article belongs to the Special Issue Angiogenesis Inhibitors)
View Full-Text   |   Download PDF [789 KB, uploaded 2 December 2011]   |  

Abstract

Angiogenesis, a neovascularization process induced from the existing parent blood vessels, is a prerequisite for many physiological and pathological conditions. Under physiological conditions it is regulated by a balance between endogenous angioinhibitors and angioactivators, and an imbalance between them would lead to pathological conditions such as cancer, age-related macular degeneration (AMD), diabetic retinopathy, cardiovascular diseases, etc. Several proteolytically generated endogenous molecules have been identified which exhibit angioinhibition and/or antitumor activities. These angioinhibitors interact with endothelial and tumor cells by binding to distinct integrins and initiate many of their intracellular signaling mechanisms regulating the cell survival and or apoptotic pathways. The present review will focus on the extracellular matrix derived angioinhibitors, and their mechanisms of actions that point to the clinical significance and therapeutic implications.
Keywords: extracelluar matrix; endogenous angioinhibitors; tumor angiogenesis; arresten; canstatin; tumstatin; endostatin; endorepellin; angiostatin; prothrombin kringle domain 2; thrombospondin; vasohibin; PEX domain; integrin signaling extracelluar matrix; endogenous angioinhibitors; tumor angiogenesis; arresten; canstatin; tumstatin; endostatin; endorepellin; angiostatin; prothrombin kringle domain 2; thrombospondin; vasohibin; PEX domain; integrin signaling
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Boosani, C.S.; Sudhakar, Y.A. Proteolytically Derived Endogenous Angioinhibitors Originating from the Extracellular Matrix. Pharmaceuticals 2011, 4, 1551-1577.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top